NEURAVI LIMITED

Their core work

Neuravi Limited is an Irish medical device company based in Galway, specializing in neurovascular intervention — most notably mechanical thrombectomy devices used to treat acute ischemic stroke by physically removing blood clots from cerebral vessels. In H2020, they contributed medical device industry expertise to computational stroke research, helping translate real-world device knowledge into virtual patient models and in-silico clinical trial frameworks. They have also been involved in implantable biosensor research, specifically electrochemical glucose sensing with long-term stability under physiological conditions. Their role in EU research is consistently that of an industry anchor — bringing practical device development experience into academic and computational science consortia.

What they specialise in

How they've shifted over time

Neuravi's early H2020 engagement (INSIST, 2017) was tightly focused on their core business domain — acute ischemic stroke, mechanical thrombectomy, and the use of virtual patient populations to support medical device and pharma clinical trials. Their later involvement (ImplantSens, 2019) marks a notable pivot toward implantable sensor technology: enzyme design, foreign body response mitigation, and long-term electrochemical stability for glucose sensing. This shift suggests they were either diversifying their technology base toward continuous monitoring devices or contributing sensing expertise that complements neurovascular intervention.

Neuravi appears to be moving from pure neurovascular intervention toward broader implantable device technology, including continuous biosensing — a direction consistent with the medical device industry's push toward real-time physiological monitoring.

How they like to work

Neuravi has never coordinated an H2020 project, always joining as a participant or third party — the classic role of an industry partner lending real-world device expertise to research-led consortia. Their 25 unique partners across 12 countries from just two projects indicates they joined relatively large, multi-national consortia rather than small bilateral partnerships. This profile is typical of a medical device SME-to-mid-size company that adds commercial and regulatory credibility to academic teams without taking on project management responsibilities.

Neuravi has collaborated with 25 unique partners across 12 countries through only 2 projects, indicating participation in large, geographically diverse consortia. Their network spans European research institutions and industry players in the health and biomedical engineering space.

What sets them apart

Neuravi occupies a rare position as an Irish medical device company with direct, commercial-stage expertise in mechanical thrombectomy — one of the most technically demanding areas of neurovascular intervention. Unlike university spin-offs or research institutes, they bring regulatory experience and real device development cycles to research consortia, which is precisely what in-silico trial projects need to remain clinically credible. Their secondary foray into implantable biosensors suggests a technology base broad enough to contribute to multiple device categories beyond stroke.

Highlights from their portfolio

• INSIST
  A large RIA project bridging medical device industry practice with computational medicine, where Neuravi's mechanical thrombectomy expertise directly informed the design of virtual stroke patient populations for in-silico trials — a high-impact use of industry knowledge in regulatory science.
• ImplantSens
  An MSCA training network focused on a technically ambitious challenge — making glucose biosensors stable enough for long-term implantation — marking Neuravi's expansion beyond neurovascular devices into continuous physiological monitoring.